about
Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitusMutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction.Identification and importance of brown adipose tissue in adult humansDissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing toolsMendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetesLoss-of-Function Mutations in APPL1 in Familial Diabetes MellitusThe +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic menSerum resistin and kidney function: a family-based study in non-diabetic, untreated individualsThe SH2B1 obesity locus is associated with myocardial infarction in diabetic patients and with NO synthase activity in endothelial cellsGenetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.SerpinB1 Promotes Pancreatic β Cell ProliferationGenome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes.A hierarchical and modular approach to the discovery of robust associations in genome-wide association studies from pooled DNA samples.Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based studyHigh-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-upAssociation of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes.GRB10 gene and type 2 diabetes in Whites.Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients.Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study.The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides levels among diabetic subjects.Joint effect of insulin signaling genes on all-cause mortality.Serum resistin and glomerular filtration rate in patients with type 2 diabetes.Genetic Variant at the GLUL Locus Predicts All-Cause Mortality in Patients With Type 2 DiabetesCirculating TNF receptors 1 and 2 predict ESRD in type 2 diabetesJoint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance.Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance.Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease.Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes.Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol studyGenome-wide linkage screen for stature and body mass index in 3.032 families: evidence for sex- and population-specific genetic effects.The TRIB3 Q84R polymorphism and risk of early-onset type 2 diabetesVariants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterolThe role of HSP70 on ENPP1 expression and insulin-receptor activation.Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice.Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes.Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
P50
Q22010745-C67B4A42-85A6-4EA2-B79E-257BFBD4A619Q24323297-D93439CA-A7AE-41CD-AEC2-ED32C3A1CBA4Q24632425-E1034065-D9B7-471D-A452-A9CE0506EDE0Q26785684-9E53FE43-C4A2-476B-B641-56207B7B26AEQ26861535-82FB8C3D-2E89-4FF5-B6FB-EDB06AA0FEB1Q28115902-0EAA1D12-5CFA-4F87-B2CA-7826CE4B0125Q28174407-474C7A6A-772C-4D19-A0B8-29EC65296511Q28728576-0058AF4C-734B-47B6-A37E-57B748CF82AEQ30010239-C2622178-1821-48A2-95D0-5B8A8B594774Q30276113-C211A6F6-763E-46EF-93C9-3ACB3A549CE1Q30354433-E4531F5C-80BD-436D-B603-A272B67D0F09Q30435965-BCCA8CCB-890E-44E8-B5D2-7921D79A3518Q33314661-F794352D-AEF6-4261-AE99-F51D0DC765C3Q33708033-1C9D028A-47C7-43A6-AFB2-218E2D79D35BQ33873169-3B5F7F1A-CD3B-4AE8-B39E-0C6A6FDF18B1Q34130317-162FE14D-B40B-49EB-A46E-4F8E1FF236C3Q34187109-12249B04-7FB6-43FF-A106-E3244520795BQ34237680-AB9277AA-713D-4057-A0A1-1E6FF7CC5F5EQ34456901-6CF99735-506D-4228-BF32-CFBFE18DF221Q34615287-2CB7D217-C8B6-4484-BD9D-9580CCF6829CQ34718476-D53DA6A8-70EA-42F0-8F6F-D933CE61548CQ34949818-3D13973F-4386-47B1-9C6A-090E803939D3Q34954938-E73546FD-3DC1-49FC-8C13-4F6713CF0F65Q35219743-AB3BA914-2BFD-420B-924F-1315405E0642Q35769598-A803CF49-184D-4639-9CC9-96E6E0ED68C5Q35804201-5A92D8C6-12F7-4883-BAF7-E66D6ADA4A55Q36487212-CF6DD1F3-BCDE-4F3A-B4DB-641D79C6B9D5Q36594956-15620FBD-1AB7-456B-BBF6-83580B0F411EQ36736922-871332D3-EFC4-4D5E-8B11-725A8CDC1EDDQ36915682-AE816444-AB45-49C2-BFB2-E59E18DA74BCQ36988877-32E4F593-8B73-44E4-9405-F82CC913BB50Q37066439-56230CD9-3095-44E6-8A23-8DEF6CCEC1D6Q37072688-73551319-A1CB-40A9-8659-04CBAD347274Q37127230-E145457E-A61A-4013-B6CD-AA7355952961Q37140562-65DAEC2E-F21F-4008-BA94-E5E202B63185Q37330834-3D4BAF57-9D35-4638-AE12-FC581FC53F1DQ37382378-67598EA4-71F3-4BCA-9283-553ABBCDE755Q37403180-26EC6544-1978-479D-A1B9-D0AC28140176Q38593433-2F65BD34-FD8C-44DF-AF76-12315FD0DAE4Q38732291-B7BC868D-A2A4-4732-8013-8A5B6B667713
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Doria
@ast
Alessandro Doria
@en
Alessandro Doria
@es
Alessandro Doria
@nl
Alessandro Doria
@sl
type
label
Alessandro Doria
@ast
Alessandro Doria
@en
Alessandro Doria
@es
Alessandro Doria
@nl
Alessandro Doria
@sl
prefLabel
Alessandro Doria
@ast
Alessandro Doria
@en
Alessandro Doria
@es
Alessandro Doria
@nl
Alessandro Doria
@sl
P108
P106
P1153
7102703833
P21
P31
P496
0000-0002-3830-4304